Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
4(57%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_2
1
14%
Ph phase_3
2
29%
Ph phase_1
4
57%

Phase Distribution

4

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
4(57.1%)
Phase 2Efficacy & side effects
1(14.3%)
Phase 3Large-scale testing
2(28.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

7

all time

Status Distribution
Active(4)
Completed(2)
Other(1)

Detailed Status

Recruiting4
Completed2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
4
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (57.1%)
Phase 21 (14.3%)
Phase 32 (28.6%)

Trials by Status

completed229%
recruiting457%
unknown114%

Recent Activity

4 active trials
Showing 5 of 7
recruitingphase_1

64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

NCT04868604
recruitingphase_3

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

NCT06056830
recruitingphase_3

64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer

NCT06970847
recruitingphase_2

Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy

NCT06907641
completedphase_1

64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)

NCT05249127
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT04868604Phase 1

64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

Recruiting
NCT06056830Phase 3

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Recruiting
NCT06970847Phase 3

64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer

Recruiting
NCT06907641Phase 2

Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy

Recruiting
NCT05249127Phase 1

64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)

Completed
NCT04839367Phase 1

Positron Emission Tomography (PET) Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA (PROPELLER)

Completed
NCT05286840Phase 1

64Cu-SAR-bisPSMA Positron Emission Tomography of Patients With Known or Suspected Prostate Cancer

Unknown

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7